PF
URGN icon

Phoenix Financial’s UroGen Pharma URGN Stock Holding History

Phoenix Financial’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,353
Closed -$208K – 439
2021
Q3 		$208K Sell
12,353
-365,985
-97% -$5.8M ﹤0.01% 394
2021
Q2 		$5.78M Sell
378,338
-240,380
-39% -$4.35M 0.11% 143
2021
Q1 		$12M Sell
618,718
-200,964
-25% -$4.27M 0.27% 97
2020
Q4 		$14.8M Sell
819,682
-82,297
-9% -$1.72M 0.4% 87
2020
Q3 		$16.4M Buy
901,979
+4,515
+0.5% +$102K 0.69% 55
2020
Q2 		$22.3M Buy
897,464
+13,996
+2% +$342K 0.94% 38
2020
Q1 		$15.4M Buy
883,468
+48,729
+6% +$1.32M 0.78% 45
2019
Q4 		$27.7M Buy
834,739
+154,007
+23% +$4.2M 1.16% 29
2019
Q3 		$15.5M Buy
+680,732
New +$22.3M 0.73% 61

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HCM
Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Phoenix Financial's URGN Position: Q4 2021 in Review

Phoenix Financial sold out of UroGen Pharma (URGN) in Q4 2021, closing a stake of 12,353 shares — an estimated $208K sold.

Phoenix Financial first reported a position in URGN in Q3 2019 and held it in 9 quarters. The position peaked at $27.7M in Q4 2019. 77 funds tracked by Wall St. Rank hold URGN as of Q4 2021.

  • Phoenix Financial reported no remaining UroGen Pharma position as of Q4 2021 after selling out during the quarter.
  • Phoenix Financial sold 12,353 UroGen Pharma shares in Q4 2021, an estimated $208K.
  • Phoenix Financial first reported a position in UroGen Pharma in Q3 2019 and held it in 9 quarters.
  • Phoenix Financial's UroGen Pharma position peaked at $27.7M in Q4 2019.
  • 77 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2021.

Based on Phoenix Financial's 13F filing for Q4 2021, filed 7 Feb 2022.